
IndraLab
Statements
reach
"EGFR mutants promote tumorigenesis of NSCLC by constitutively activating downstream signaling effectors, including PI3K/AKT, RAS/ERK, and others.30, 31 Activated AKT, as a key downstream effector of the EGFR pathway, has been reported to activate NF‐κB and thereby regulate PD‐L1 expression."
reach
"XREF_BIBR The results showed that mutant EGFR selectively activated Akt and signal transducer and activator of transcription (STAT) signaling is related to cell survival; however, mutant EGFR could not act on extracellular signal regulated kinase signaling, the function of which is to induce proliferation."
reach
"For example, certain mutations of epidermal growth factor receptor (EGFR) extracellular and kinase domains lead to downstream overactivation of signaling pathways, such as Ras–mitogen activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt), which play a major role in cell proliferation and survival [8,9]."
reach
"43 In non-small cell lung cancer (NSCLC), EGFR mutations promote proliferation, inhibit apoptosis and migration, and then promote tumor progression by activating the PI3K/AKT and JAK/STAT signaling pathways.44 Therefore, EGFR and the JAK/STAT and PI3K/Akt signaling pathways are closely related."
reach
"Gefitinib induced substantial clinical responses and reduced tumour burden in ~ 10% of patients with chemotherapy-refractory non small cell lung cancers; however, the majority of these patients had EGFR mutations that constitutively activated the antiapoptotic protein AKT (Baselga, 2002; Fukuoka et al, 2003; Kris et al, 2003; Giaccone et al, 2004)."